Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

(2014) Matthieu Mahévas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists

(2013) Bahareh Ghadaki et al.   TRANSFUSION

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

(2012) M. N. Saleh et al.   BLOOD

Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

(2012) James B. Bussel et al.   BRITISH JOURNAL OF HAEMATOLOGY

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

(2010) W. Bao et al.   BLOOD

Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters

(2010) Lisa J. Toltl et al.   BRITISH JOURNAL OF HAEMATOLOGY

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Biology and Chemistry of Thrombopoietic Agents

(2010) David J. Kuter   SEMINARS IN HEMATOLOGY

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Novel Thrombopoietic Agents

(2008) Roberto Stasi et al.   DRUGS